Renal clear cell carcinoma (ccRCC) is characterized by frequent mutation in SETD2, which has recently been shown to regulate mismatch repair (MMR). We aim to investigate the association between MMR machinery genes and SETD2 mutation in ccRCC. We exploited the Genomics of Drug Sensitivity in Cancer (GDSC) database to identify selective inhibitors for SETD2 mutant ccRCC cells. We also exploited the Cancer Genome Atlas (TCGA) database to study the association between SETD2 status and MMR-related genes. In vitro studies were performed to validate the in silico findings. Reproduction of the GDSC database revealed four compounds with significant selectivity for SETD2 mutant ccRCC cells, amongst which two compounds targeted PI3Kβ. Phosphorylation of AKT at both S473 and T308 was decreased following PI3Kβ inhibitor treatment in SETD2 mutant ccRCC cells, whereas the basal pAKT level was not changed between mutant and wild-type SETD2. Both decreased MLH1 and increased AKT levels induced lower PMS2, indicating that MMR was mediated by SETD2 via both AKT and MLH1 in ccRCC. Analysis of the TCGA database further revealed high tendency of homozygous co-deletion of SETD2 and MLH1. In the absence of MLH1, suppression of pAKT by PI3Kβ inhibitor was mitigated and inhibition in cell proliferation, invasiveness, migratory ability and tumourigenesis was partially restored. Besides the reported H3K36-trimethylation pathway, we found that SETD2 mutation also mediated MMR via AKT-induced PMS2 decrease and co-loss of MLH1 loss in ccRCC.
Clear cell renal cell carcinoma SETD2 MMR MLH1
This is a preview of subscription content, log in to check access.
This study was supported in part by Youth Scientific Funding of Shanghai Municipal Commission of Health and Family Planning (20144Y0111).
CF, HW, and QD designed the study. CF, GD, and HW prepared the figures. CF, GD, and HW did the statistics. CF sketched the manuscript. ZW and QD reviewed the article. All authors approved the final version of the manuscript.
Wen H et al. Med19 promotes bone metastasis and invasiveness of bladder urothelial carcinoma via bone morphogenetic protein 2. Ann Diagn Pathol. 2013;17:259–64.CrossRefPubMedGoogle Scholar
Feng C-C et al. Expression of pigment epithelium-derived factor and tumor necrosis factor-α is correlated in bladder tumor and is related to tumor angiogenesis. Urol Oncol Semin Original Investig. 2013;31:241–6.CrossRefGoogle Scholar
Rubio-Del-Campo A et al. Implications of mismatch repair genes hMLH1 and hMSH2 in patients with sporadic renal cell carcinoma. BJU Int. 2008;102:504–9.CrossRefPubMedGoogle Scholar
Dail, M. et al. Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature (2014).Google Scholar
Choi YJ et al. Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability. Hum Pathol. 2014;45:1674–81.CrossRefPubMedGoogle Scholar
Hakimi AA et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res. 2013;19:3259–67.CrossRefPubMedPubMedCentralGoogle Scholar
Schmidt CK, Jackson SP. On your mark, get SET(D2), go! H3K36me3 primes DNA mismatch repair. Cell. 2013;153:513–5.CrossRefPubMedGoogle Scholar
Jia J et al. A novel function of protein kinase B as an inducer of the mismatch repair gene hPMS2 degradation. Cell Signal. 2013;25:1498–504.CrossRefPubMedGoogle Scholar
Stoehr C et al. Mismatch repair proteins hMLH1 and hMSH2 are differently expressed in the three main subtypes of sporadic renal cell carcinoma. Pathobiology. 2012;79:162–8.CrossRefPubMedGoogle Scholar
Singh RB, Amare Kadam PS. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC). Urol Oncol. 2013;31:1333–42.CrossRefPubMedGoogle Scholar